Apremilast, secukinumab, and ustekinumab found equally efficacious and safe for psoriatic arthritis patients

Primary tabs

NEWS
Apremilast, secukinumab, and ustekinumab found equally efficacious and safe for psoriatic arthritis patients

Psoriatic arthritis is chronic arthritis. In a few people, it is mild, with just occasional flare-ups. In other people, it is continuous and can cause joint damage if it is not treated. Early diagnosis is essential to avoid damage to joints. Psoriatic arthritis typically occurs in people with skin psoriasis, but it can happen in subjects without skin psoriasis, particularly in peoples who have relatives with psoriasis.

For most people, appropriate treatments will relieve pain, protect the joints, and maintain mobility. Physical activity helps keep the joint movement. Psoriatic arthritis usually occurs in people between the ages of 30 to 50 but can begin as early as childhood. Males and females are equivalently at risk. Children with psoriatic arthritis are also at the chance to develop uveitis (inflammation of the middle layer of the eye). To assess the relative effect and safety of apremilast, secukinumab, and ustekinumab at variable doses in patients with active psoriatic arthritis (PsA).

A Bayesian network meta-analysis was conducted, which involved randomised controlled trials (RCTs) that evaluated the effect and safety of secukinumab 75 mg, secukinumab 150 mg, secukinumab 300 mg, apremilast 20 mg, apremilast 30 mg, ustekinumab 45 mg, and ustekinumab 90 mg differentiate with placebo. Of the RCTs, eight contain 3289 patients met the incorporation scale. The American College of Rheumatology (ACR) 20 counter rate was consequently greater in the secukinumab 300 mg group than in the placebo group. Secukinumab 150 mg, secukinumab 75 mg, ustekinumab 45 mg, ustekinumab 90 mg, and apremilast 20 mg, apremilast 30 mg, were also more effective than placebo. There were no consequent differences in the efficacy of the interventions. A dose-response association among the same drug groups was determined. The number of serious adverse events was not consequently different among the apremilast, secukinumab, ustekinumab, and placebo groups.

All drug therapies were more efficacious than placebo; however, there were no significant differences in the efficacy and safety of the drugs at different doses.

Source:

Z Rheumatol. 2017 Aug 8

Link to the source:

https://www.ncbi.nlm.nih.gov/pubmed/28791450

Original title of the article:

Relative efficacy and safety of apremilast, secukinumab, and ustekinumab for the treatment of psoriatic arthritis.

Authors:

Song; G. G. et al.

SearchTags: 
Therapeutic, Apremilast, Secukinumab, Ustekinumab, Psoriatic arthritis, Chronic, Meta-analysis, Randomized controlled, Efficacy, Safety
Log in or register to post comments